SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.36+3.4%10:31 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9326)10/23/2003 3:45:18 PM
From: Ian@SI  Read Replies (1) of 52153
 
Peter,

I'm listening to the QLTI call now. Paul Hastings believes that Combination therapy with the VEGF drugs, if and when they're approved, is most likely.

Visudyne is effective against existing abnormal blood vessels. The VEGF stuff is targeted at preventing/reducing their growth.

So best case, if Macugen gets approved, QLTI could end up with another marketing partner, and not have to pay them any royalty for their effort. ;-)

Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News